BioSpace News Archive

The delays, particularly in the regulatory review process, have caused the merger completion to be pushed back to the second half of this year.

“We are fortunate to have the strong support of investors aligned with our mission to provide lasting relief of all symptoms of diabetic peripheral neuropathy,” said Simon Jones, Regenacy’s president and chief executive officer.

Bristol-Myers Squibb Company (NYSE: BMY) will announce results for the first quarter of 2020 on Thursday, May 7, 2020. During a conference call at 8:30 a.m. ET on May 7, 2020, company executives will review financial information and address inquiries from analysts. Investors and the general public are invited to listen to a live webcast of the call at bms.com/investors or by dialing in the U.S. toll free 888-256-1007

Results demonstrate that treatment with Reblozyl provides significant reduction in transfusion burden for patients with beta thalassemia-associated anemia compared to placebo

Treatment of COVID-19 with ExThera’s Seraph®100 Microbind® Affinity Blood Filter (Seraph 100) has begun in hospitals in Germany and Italy. Seraph 100 treatments of COVID-19 are also expected to begin soon in France and the USA. Seraph 100 is the only ‘hemoperfusion device’ approved for the reduction of pathogens in blood. In recent EU clinical cases improved lung function and rapid reduction of dru

Scholar Rock Announces Publication in Science Translational Medicine of Preclinical Data Detailing a Potent and Selective Inhibitor of TGFβ1 Overcoming Primary Resistance to Checkpoint Inhibition

Unum Therapeutics Inc. today announced financial results for the fourth quarter and full year ended December 31, 2019, and provided corporate updates. “We recently announced the conclusion of our Phase 1 ACTR707 programs and restructuring to prioritize our capabilities and resources towards advancing our preclinical program, BOXR1030

Lumos Diagnostics and Planet Innovation, its strategic investor and partner, have mobilized a philanthropic effort to provide the FebriDx® diagnostic test to general practitioners and other healthcare professionals in the state of Victoria.

Candida auris is another growing and serious infectious global health threat that particularly impacts healthcare settings. In the United States there were more than 1,000 clinical cases and 2,000 colonized patients reported by the CDC as of February 6, 2020

Aprea Therapeutics, Inc. , today reported financial results for the three months and year ended December 31, 2019 and provided a corporate update. Corporate Update: The Company is conducting, supporting and planning multiple clinical trials of APR-246: Pivotal Phase 3 MDS Trial— The